REG - Oxford BioDynamics - OBD launches 94% accurate PSE test in US and UK

Oxford BiodynamicsAnnouncement

26/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230926:nRSZ5985Na&default-theme=true

RNS Number : 5985N  Oxford BioDynamics PLC  26 September 2023

Oxford BioDynamics Plc

Oxford Biodynamics launches the 94% accurate EpiSwitch® Prostate Screening

blood test (PSE) for men with prostate cancer risk in the US and UK

·    Validation completed in OBD's US CLIA-certified clinical laboratory
ahead of time - enabling immediate launch of the EpiSwitch Prostate Screening
(PSE) test

·    PSE is designed to run alongside a standard PSA test

·    PSE boosts PSA predictive accuracy from 55% to 94% for determining
the presence or absence of prostate cancer

·    Increased accuracy of diagnosis significantly reduces false
positives, thus decreasing unnecessary referrals for invasive biopsies

 

Oxford, UK - 26 September, 2023 - Oxford BioDynamics, Plc (AIM: OBD, the
Company), a biotechnology company developing precision medicine tests based on
the EpiSwitch® 3D genomics platform, announces that validation of its
EpiSwitch Prostate Screening (PSE) test in its US clinical (CLIA-certified)
laboratory is now complete, ahead of schedule.

Coinciding with Prostate Cancer Awareness month, OBD has brought forward the
launch of its highly accurate, 94% precision medicine test to make it
immediately available to men being screened for prostate cancer. This includes
those who have received an elevated prostate-specific antigen (PSA) result as
well as many others where prostate cancer is a clinical concern.

EpiSwitch Prostate Screening test (PSE)

The current blood screening test, the PSA test, is only 55% accurate, and is
considered an unreliable test by many doctors, including the NHS in the UK(1).
If results show an elevated PSA level, then patients face a dilemma - retest
with PSA even with its low accuracy, or go for more invasive screening methods
such as a prostate biopsy which has the potential for other health risks.(1)
Now there is an alternative.

The PSE test is the culmination of nearly a decade's long collaboration
between OBD, Imperial College London, University of East Anglia, Imperial
College NHS Trust and UK's leading prostate cancer experts as part of the
PROSTAGRAM screening pilot. The results of this trial were published in the
peer reviewed publication, Cancers(2) in February this year.

The PSE test is designed to run alongside a standard PSA test, and combines
the PSA score with five proprietary epigenetic biomarkers to predict, with 94%
accuracy, the presence (or absence) of prostate cancer.(2) Those with a PSE
result of low likelihood of cancer can be placed on active surveillance and
retested later without being referred for an invasive and often destructive
biopsy. A high likelihood result would necessitate referral to a Urologist for
further investigation.

As well as very high accuracy, PSE has high specificity of 97% (PSA: 53%) and
sensitivity of 86% (PSA: 64%), along with both high positive, 93% (PSA: 25%),
and high negative, 95% (PSA: 86%), predictive values to assess the risk of
prostate cancer in men.(2) It has been validated as a laboratory developed
test (LDT) in OBD's CLIA-certified testing laboratory in Frederick, Maryland.

More information is available at: www.94percent.com (http://www.94percent.com)
.

"PSE is a diagnostic prostate cancer test with unprecedented accuracy." said
Mathias Winkler, M.D., F.R.C.S., Consultant Urologist and Surgeon, Charing
Cross Hospital and Imperial College London. "Nine of 10 cancers are found
compared to 3 of 10 with PSA alone. Likewise, false-positive results are
reduced avoiding unnecessary anxiety and expense. This is clearly highly
desirable for men who are health-conscious or at risk of prostate cancer. We
are delighted to be part of the team evaluating and refining the test for use
in particular risk groups (black men) and prospectively validating in a larger
patient cohort compared to current standard of care."

The Company is continuing to work alongside the Norwich Medical School,
University of East Anglia, and Imperial College NHS Healthcare Trust, with
support from Prostate Cancer Research, to actively investigate the elevated
prevalence of prostate cancer in the black population (link here
(https://www.uea.ac.uk/news/-/article/uea-launches-project-to-better-detect-prostate-cancer-in-black-men)
).

The PSE test is being launched during Prostate Cancer Awareness month to
introduce both physicians and patients to the benefits of this highly accurate
blood test. Before today, following an elevated PSA result, men and their
primary care physicians faced the cancer screening dilemma; retest PSA even
with its low accuracy, schedule an MRI or send the patient, maybe needlessly,
for an invasive biopsy.(3) This is where the 94% accurate PSE can resolve the
conundrum. Because PSA is just one component of the PSE test, PSE works with
all PSA values from low to high as not all high PSA values will return a high
likelihood result just as some low PSA values will.

"Although the traditional PSA has demonstrated clinical utility in prostate
cancer screening and monitoring, it also has limitations that are
well-described," said Dr. Phillip Pierorazio, Section Chief of Urology at Penn
Presbyterian Medical Center, and Professor of Surgery at the Hospital of
University of Pennsylvania. "A more sensitive and specific test would have the
potential to increase diagnostic accuracy and address some of the current
challenges with prostate cancer screening."

Patients should speak to their doctor about ordering the PSE test.  Their
doctor will submit a test requisition and arrange for a small sample of the
patient's blood to be collected.  Test results will be returned to the
ordering physician within five days after the blood sample is received in the
laboratory.

More information may be found at www.94percent.com (http://www.94percent.com)
. Please contact Oxford BioDynamics client services anytime by emailing the
team at  pse.test@myobdx.com.

UK immediate access

The PSE test will be immediately available to men in the UK using the US
testing facility to process results initially. OBD is in the process of
obtaining ISO15189 certification for a clinical lab within its Oxford, UK
laboratory. Once certified, expected early in 2024, precision medicine tests,
like EpiSwitch PSE, will be run there - shortening the overall turnaround time
for results.

More information may be found at www.94percent.com (http://www.94percent.com)
. Please contact Oxford BioDynamics client services anytime by emailing the
team at  pse.test@myobdx.com.

"There is a clear need in everyday clinical practice for a much more accurate
blood test that can screen men for prostate cancer and accurately identify
those at risk, while sparing those who up to now would be subject to
unnecessary, expensive, and invasive procedures. It feels wholly appropriate
that the early launch of the test coincides with Prostate Cancer Awareness
month," said Dr Jon Burrows, OBD's Chief Executive Officer. "With the news
today of the launch of another EpiSwitch-based product, we are continuing to
improve patient health whilst also reducing the cost of care."

Proof Sources

1.    NHS Health A to Z. Prostate cancer: PSA testing (2021).
https://www.nhs.uk/conditions/prostate-cancer/psa-testing

2.    "Circulating Chromosome Conformation Signatures Significantly Enhance
PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer
Detection". Cancers. 2023; 15(3):821. Pchejetski D, Hunter E, Dezfouli M, et
al.

3.    "Should I have a PSA test?" National Health System - United
Kingdom.  https://www.nhs.uk/conditions/prostate-cancer/ "Diagnostic accuracy
of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired
validating confirmatory study". Lancet. Ahmed, Bosaily, Brown, et al.

-Ends-

For more information:

 Oxford BioDynamics Plc                   Tel: +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser        Tel: +44 (0)20 7408 4090

 Stephane Auton / Iain Sexton

 Instinctif Partners - media              UK Tel: +44 7890022814 /

 +44 7580 993585
 Melanie Toyne-Sewell / Rozi Morris /

                                        US Tel: +1 9178657226 /
 Adam Loudon (UK & RoW media)
+1 650 728 0227

 Tegwyn Collins /Mike Gaynes (US media)   OxfordBioDynamics@instinctif.com

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(http://www.94percent.com) (EpiSwitch Prostate Screening test) blood tests.
CiRT is a predictive immune response profile for immuno-oncology (IO)
checkpoint inhibitor treatments, launched in February 2022. PSE is a blood
test that boosts the predictive accuracy of a PSA test from 55% to 94% when
testing the presence or absence of prostate cancer, which has been launched in
the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFELLLXKLXBBL